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INTRODUCTION 
Drug delivery technologies are now receiving 
considerable attention from pharmaceutical companies. 
The main purpose of developing alternative drug 
delivery technologies is to increase efficiency and safety 
of drug delivery and provide more convenience for the 
patient. Substantial research conducted during the past 
several years has lead to the development of technologies 
that meet the requisite criteria for delivering the drug 
through a non-invasive route 1. One of such technologies 
is transdermal drug delivery. Transdermal drug delivery 
system is topically administered medicaments in the 
form of patches that deliver drugs for systemic effects at 
a predetermined and controlled rate 2. 
Transdermal drug delivery is the non-invasive delivery 
of medications from the surface of the skin which is the 
largest and most accessible organ of the human body 
through its layers, to the circulatory system. Medication 
delivery is carried out by a patch that is attached to the 
body surface. Transdermal patch is a medicated adhesive 
pad that is designed to release the active ingredient at a 
constant rate over a period of several hours to days after 
application to the skin 1.  
At present, the most common form of delivery of drugs 
is the oral route. While this has the notable advantage of 
easy administration, it also has significant drawbacks -- 
namely poor bioavailabiltity due to hepatic metabolism 
(first pass) and the tendency to produce rapid blood level 
spikes (both high and low), leading to a need for high 
and/or frequent dosing, which can be both cost 
prohibitive and inconvenient.3 
To overcome these difficulties there is a need for the 
development of new drug delivery system; which will 
improve the therapeutic efficacy and safety of drugs by 
more precise (ie site specific ) , spatial and temporal 
placement within 
the body thereby reducing both the size and number of 
doses.4 
Terbutaline Sulphate is widely used for the therapeutic 
management of chronic as well as prophylaxis of asthma 
and nocturnal asthma in particular. But it has several 
drawbacks such as short biological half-life of about 3.6 
hours 5, it is readily metabolized in the gut wall and liver 
when given orally. It has a short duration of action, low 
peak plasma level of 1.2 µg/ml and poor bioavailability 
of only 14.8% 6. These factors necessitated formulation 
of controlled release transdermal drug delivery system 
for terbutaline sulphate. 
 
ABSTRACT 
The aim of the study is to formulate matrix based transdermal patch for water soluble drug like terbutaline and to study the 
effect of formulation composition on physical property, to study permeation profile of the patches through hairless mice skin 
and to study release profile of the patches. Five monolayered terbutaline sulphate transdermal patches bearing a rate controlling 
membrane were prepared by solvent-casting technique. Five formulations were prepared with varying concentrations of 
sodium alginate- FI, FII, FIII, FIV and FV with 350mg, 450mg, 250mg, 400mg and 300mg respectively. The 15mg terbutaline 
sulphate, 0.5ml glycerine and 0.1% chlorocresol were used along with sodium alginate in preparation of drug matrix.  A 
mixture of ethylcellulose, chloroform and dichloromethane were used for preparation of rate controlling membrane using 
dibutylphthalate as a plasticizer.  
 The physicochemical characteristics of the patches were evaluated by standard techniques. In-vitro drug release test was done 
in Keshary Chein diffusion cell by using skin of albino mice for 6 hours study. From the in-vitro permeation release study, 
formulation FII, FIV and FV followed Higuchi order kinetics while FI followed Peppas equation and FIII followed first order 
kinetics. Formulation FII showed more permeability than other formulations due to high concentration of sodium alginate in 
the FII. Thus the release of drug was found to be directly related to the concentration of SA. 
Key words: Sodium alginate; Terbutaline Sulphate; Drug matrix; Rate controlling membrane; Drug release study; In-vitro drug 
permeation study 
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MATERIALS AND METHODS 
Materials 
Terbutaline sulphate, Chlorocresol and Ethyl cellulose 
MCCP PH 102 was received as a gift sample from Nepal 
Pharmaceutical Pvt. Ltd. (NPL), Bara. The rest 
ingredients and reagents were of analytical grade. 
Equipments and Instruments 
Keshary Chein diffusion cell, Analytical Balance, 
UV/Visible spectrophotometer, Microprocessor pH 
meter, Magnetic Stirrer with Hot plate, Micrometer 
screw gauge, Hot Air Oven, Albino mice received from 
animal house, Aluminium foil, Glass mould 
Preparation of Terbutaline Drug Matrix 
The drug polymer solution (composition given in Table 
1) was transferred into a mould of size 22×22 cm2, 
previously covered with a backing membrane, 
aluminium foil. The mould was then kept in a hot air 
oven and maintained at a temperature of 60°C for 12 
hours. The composition of the drug matrix is shown in 
Table 1.  
For the preparation of drug polymeric solution for each 
4.9cm2, 15mg of terbutaline sulphate was dissolved in 5 
ml water. 0.5 ml glycerine and chlorochresol 1% was 
also added. Then sodium alginate (SA) was added with 
continuous stirring. The solution was homogeneously 
mixed. Sufficient water was added to maintain the 
viscosity.
 
Table 1: Formulation of Drug Matrix 
Formulation  Terbutaline 
Sulphate 
(mg) 
Sodium 
Alginate 
(mg) 
Water 
(ml) 
Glycerine 
(ml) 
Chlorcresol 
(%) 
FI 15 350 5 0.5 0.1 
FII 15 450 5 0.5 0.1 
FII 15 250 5 0.5 0.1 
FIV 15 400 5 0.5 0.1 
FV 15 300 5 0.5 0.1 
 
Preparation of Rate Controlling Membrane 
Ethyl cellulose was dissolved in a mixture of chloroform 
and dichloromethane. Dibutylphthalate was used as a 
plasticizer, and the solution was poured in the previously 
dried drug matrix and left for drying. The composition of 
rate controlling membrane for each patch is given in the 
Table 2.
 
Table 2: Formulation of rate controlling membrane 
Composition Amount  
Ethyl Cellulose 25 mg 
Chloroform 2.5 ml 
Dichloromethane 3 ml 
Dibutyl Phthalate 45 mg 
 
Evaluation of physical parameters 
Weight Variation: The patch of diameter 2.5 cm were cut 
and was weighed for 10 patches of each formulation. The 
data were presented in ± standard deviation. 7 
Thickness Variation: Thickness was measured using 
screw gauze at different points of the film. The 
thicknesses of 10 patches were measured. The data were 
presented in ± standard deviation. 7 
Diameter Variation: For each patch, diameter was 
measured at two spots by vernier calliper and its average 
was taken. It was done for 10 patches. The data were 
presented in ± standard deviation. 7 
Folding Endurance: For each patch, folding endurance 
was determined by repeatedly folding the small strip of 
film at the same place until it break. The number of times 
the films could be folded at the same place without 
breaking was the folding endurance value. 8 
Moisture content: For determination of moisture content 
the prepared patches were weighed individually and kept 
in a desiccators containing calcium chloride at room 
temperature for 24 h. The films were weighed again after 
a specified interval until they show a constant weight. 
The percent moisture content is calculated using the 
following formula. 7 
% moisture uptake = Final weight – Initial weight X 100  
                                                Initial weight  
Standard Calibration Curve 
A stock solution of Terbutaline Sulphate (500 µgm per 
ml) was prepared. Five samples of concentration 25, 50, 
75,100 and 125 µgm per ml were prepared from the 
stock solution with proper dilution using saline 
phosphate buffer (pH 7.4). The absorbance of these 
solutions was measured at 277 nm.  
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Absorbance against concentration was plotted and R2 
value showed that there was linear relationship among 
the measured value. The equation for the calculation of 
concentration of drug in content, release study and 
permeation study were calculated using the equation 
obtained from standard calibration curve. 
Assay 
The drug containing patch of 4.9cm2 area was cut into 
pieces and kept in 100 ml volumetric flask containing the 
saline phosphate buffer (pH 7.4). The volumetric flask 
was kept in the magnetic stirrer for 2 hour. The 
absorbance of the samples was measured with the help of 
spectrophotometer. The total drug content of the patch 
was determined. 
Drug Relase Study 
The patch to be studied was stuck to the inner surface 
of the lid with the glue such that the blocking 
membrane (aluminum foil) was stuck to the lid. The 
release apparatus was set such that receiver fluid 
(saline Phosphate buffer pH 7.4) would be in contact 
with the patch of the lid maintained at the temperature 
of 32°C ± 2° C. The rotation of the magnetic bead was 
maintained at 120 ± 50 rpm. The 3.4ml sample was 
drawn at interval of 0.5 hour. The amount of drug 
release was estimated by using the equation obtained 
from the standard calibration curve. 
In-vitro Drug Permeation study 
The patch to be studied was adhered to the outer surface of 
the mice skin. The skin containing patch was then fitted to 
the receiver compartment of the Keshary Chein diffusion 
cell. Receiver compartment along with skin and upper 
compartment was held together with the rubber band. The 
phosphate buffer was filled in the receiver compartment 
such that it was in contact with the skin. The magnetic 
stirrer was maintained at 120 ± 50 rpm. The temperature of 
the phosphate buffer in the receiver compartment was 
maintained at 32°C ± 2°C. Sample of 3.4 ml was drawn 
at the predetermined interval of 0.5hours and after 
withdrawing, 3.4 m1 was replaced in the receiver 
compartment at each interval. The amount of drug 
permeated was estimated by using the equation 
obtained from the standard calibration curve.  
In-vitro Drug permeation kinetics 
The various mathematical models were used to see whether 
or not permeation of drug via the mice skin followed zero 
order, First order, Peppas equation or Higuchi equation.  
Result and Discussion 
Evaluation of Physical parameters 
The physical properties of the patches are recorded in 
table 3.
 
Table 3: Physical parameters of formulated patches 
Formulation Weight variation 
(gm) 
Diameter Thickness Average 
Folding 
Endurance 
% Moisture 
Content 
FI 0.461 ± 0.17 2.5 ± 0.1 0.42 ± 0.05 721 2.990 ± 0.06 
FII 0.483 ± 0.14 2.5 ± 0.05 0.55 ± 0.10 650 8.765± 0.08 
FIII 0.488 ± 0.10 2.5 ± 0.05 0.60 ± 0.07 597 8.371± 0.04 
FIV 0.366 ± 0.11 2.5 ± 0.08 0.40 ± 0.06 743 6.250± 0.02 
FV 0.555 ± 0.14 2.5 ± 0.07 0.90 ± 0.03 197 4.393± 0.06 
 
The weight variation of FIII was found least deviated and 
FI was found highly deviated in comparison with other 
formulations. The deviation in the patch may be due to 
improper mixing or due to irregular surface of the oven 
used for drying. The thickness was found to be highest in 
FV and lowest in FIV. This may be due to improper 
mixing or due to irregular surface of the oven used for 
drying purpose. Folding endurance for all the 
formulations was very good. Folding endurance 
measures the ability of patch to withstand rupture.  The 
moisture content was found to be least in FI i.e. 2.990% 
and greatest in FII i.e. 8.765%. Generally the moisture 
content for transdermal patches should be 2-5 %. Thus 
moisture content studies showed strong moisture 
absorbing capacity, this is due to inherent property of the 
sodium alginate polymer. This observation indicates the 
use of proper packaging material. 
The physicochemical studies show the unpredictable 
characteristics of sodium alginate concentration in 
physicochemical parameters of the patch. Thus SA does 
not interfere the physicochemical parameters of the 
patch.  
Assay 
The maximum assay was found to be 91.46% of 
formulation FV and minimum was found to be 
82.13% of FII. The assay was found to be less; this 
may be due to errors in mixing, thickness, weight 
variation, etc.  
Drug Release Study 
In the release study, release from FII was found greatest 
in comparison with other formulations. The drug release 
from the patch increased compared to the permeation 
study due to absence of skin as barrier. The release 
seems to be dependent on the concentration of SA except 
FI which contain SA 350mg. This may resulted due to 
error in the rate controlling membrane, weight variation 
or due to improper mixing. 
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Fig 1: Drug release profile of formulated patches 
 
In-Vitro Drug Permeation Study 
 
Fig 2: In-vitro drug permeation profile of formulated patches 
The graph plotted between cumulative percentages of 
drug permeated against time, shows the permeation of 
drug in FII was greatest among the five formulations. It 
could be due to higher concentration of Sodium alginate 
in the formulation, 450mg of SA was used. SA was used 
in the formulation as a thickening and suspending agent 
which also helps in the formation of gels. The main 
function was to isolate and entrap the drug in the drug 
matrix. SA is hydrophilic polymer which is not suitable 
for transdermal formulation. So the membranes formed 
from hydrophobic polymers were used as rate controlling 
membrane. 
The curve obtained from in FIV and FV was nearly 
similar but the cumulative percentage drug release in 
FIV was higher due to higher concentration of SA i.e., 
400mg than FV (300mg).For the formulation FI and FII 
the release study could only be carried out for 4 hours 
due to constrain in time and electricity. 
The graph showed direct relation between concentration 
of SA and drug permeation except FIII. This may be due 
to more lag time because of the temperature of the 
receptor compartment was not maintained initially.
Maharjan et al                                    Journal of Drug Delivery & Therapeutics; 2014, 4(5), 116-120 120 
© 2011-14, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                              CODEN (USA): JDDTAO 
In-Vitro Permeation kinetics 
The in-vitro release data was treated with kinetic 
equations such as the zero order rate kinetic equation, 
first order rate kinetic equation, Higuchi’s diffusion 
equation and Peppas equation, to understand the release 
kinetics and mechanism of release from the formulated 
patch. From the in-vitro permeation release study, 
formulation FII, FIV and FV followed Higuchi order 
kinetics. One of the assumptions of Higuchi equation 
was the maintenance of perfect sink condition. The 
multilayered structure of skin could provide perfect sink 
condition and could be the reason for following Higuchi 
equation. Due to the hydrophilic property of the drug, 
aqueous layer of the skin could maintain perfect sink 
condition for the drug. This also signifies that the initial 
drug concentration in the system is much higher than the 
matrix solubility, the diffusivity of the drug is constant 
and the swelling of the polymer is negligible. FI 
followed Peppas equation and FIII followed first order 
kinetics. 
 
Table 4: In-vitro drug permeation kinetics of formulated patches 
Formulation Zero Order Kinetics First Order Kinetics Higuchi Order Kinetics Peppas Equation 
R
2
 K R
2
 k R
2
 n R
2
 n 
I 0.668 0.639 0.795 0. 057 0.894 1.593 0.901 0.246 
II 0.721 0.749 0.683 0.056 0.917 2.311 0.914 0.360 
III 0.794 1.380 0.989 0.043 0.780 2.949 0.951 0.249 
IV 0.785 0.627 0.688 0.060 0.952 2.059 0.930 0.439 
V 0.912 0.747 0.880 0.104 0.997 1.919 0.996 0.526 
 
CONCLUSION 
Transdermal patches with different concentration of 
Sodium Alginate were prepared using terbutaline sulphate 
as an active drug ingredient. Other excipients of drug 
matrix and rate controlling membrane were kept constant 
to evaluate the role of SA in drug permeation. The five 
formulations were prepared formulations I, II, III, IV and 
V using 350mg, 450mg, 250mg, 400mg and 450mg SA 
respectively and keeping other excipients and drug 
constant. The physiochemical parameters were 
determined. The physiochemical parameters do not show 
significance of concentration of SA. 
From the permeation study, it was found that the release 
and permeation of FII was greater than other 
formulations. This is due to use of higher concentration 
of SA in this formulation.  From the in-vitro permeation 
release study, formulation FII, FIV and FV followed 
Higuchi order kinetics. FI followed Peppas equation and 
FIII followed first order kinetics. 
ACKNOWLEDGEMENT 
I am very grateful towards Asian College for Advanced 
Studies for providing the required facilities to conduct 
this research work. Also I would like to express my 
gratitude to all the people who have helped me directly 
or indirectly in my research. 
CONFLICT OF INTEREST 
We authors do not have any personal or financial conflict 
regarding the publication of this manuscript. 
 
 
REFERENCES 
1. URL:http://ezinearticles.com/?Transdermal-Drug-Delivery,-
Transdermal-Patches&id=155961 
2. http://www.pharmainfo.net/reviews/transdermal-drug-
delivery-systems-review 
3. Chien, YW, Novel drug delivery systems, Drugs and the 
Pharmaceutical Sciences, 
Vol.50, Marcel Dekker, New York, NY;1992;79 
4. Girish Chopda. Transdermal Drug Delivery System: A 
Review, 12 Jan 2006. 
(http:/www.pharmainfo.net/exclusive/reviews/transdermal-
drug-delivery-system-: - a-review/) 
5. Shargel L. And YuBc A. Applied Biopharmaceutics and 
Pharmacokinetics, Appleton and Lang, Stanfoard, 1992, 3
rd
 
ed., 595 
6. Rathore RPS et al. Trandermal formulation of terbulatine 
sulphate. Priory Lodge Education Limited 2006. 
(www.priory.com)  
7. Aggarwal G. Development, Fabrication and Evaluation of 
Transdermal Drug Delivery System - A Review, Latest 
Reviews 2009; 7( 5). 
8. Nafee N. Acta Pharm., 2003, 53, 199. 
 
